Literature DB >> 32213106

Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy.

Marie K Malone1, Karly Smrekar1, Sunju Park1, Brianna Blakely1, Alec Walter1, Nicholas Nasta1, Jay Park1, Michael Considine2, Ludmila V Danilova2, Niranjan B Pandey3, Elana J Fertig2,3,4, Aleksander S Popel2,3, Kideok Jin1.   

Abstract

In triple-negative breast cancer (TNBC), the lack of therapeutic markers and effective targeted therapies result in an incurable metastatic disease associated with a poor prognosis. Crosstalks within the tumor microenvironment (TME), including those between cancer and stromal cells, affect the tumor heterogeneity, growth, and metastasis. Previously, we have demonstrated that IL-6, IL-8, and CCL5 play a significant role in TNBC growth and metastasis. In this study, we performed a systematic analysis of cytokine factors secreted from four stromal components (fibroblasts, macrophages, lymphatic endothelial cells, and blood microvascular endothelial cells) induced by four TNBC cell types. Through bioinformatic analysis, we selected putative candidates of secreted factors from stromal cells, which are involved in EMT activity, cell proliferation, metabolism, and matrisome pathways. Among the candidates, LCN2, GM-CSF, CST3, IL-6, IL-8, and CHI3L1 are ranked highly. Significantly, Lipocalin-2 (LCN2) is upregulated in the crosstalk of stromal cells and four different TNBC cells. We validated the increase of LCN2 secreted from four stromal cells induced by TNBC cells. Using a specific LCN2 antibody, we observed the inhibition of TNBC cell growth and migration. Taken together, these results propose secreted factors as molecular targets to treat TNBC progression via crosstalk with stromal components.

Entities:  

Keywords:  TNBC; secreted factors; stromal cells; tumor microenvironment; secretome

Year:  2020        PMID: 32213106      PMCID: PMC7515526          DOI: 10.1080/15384047.2020.1739484

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  69 in total

1.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

Review 2.  Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment.

Authors:  Esak Lee; Niranjan B Pandey; Aleksander S Popel
Journal:  Expert Rev Mol Med       Date:  2015-01-30       Impact factor: 5.600

3.  Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.

Authors:  Xiaohong Leng; Tian Ding; Hui Lin; Yan Wang; Limei Hu; Jianhua Hu; Barry Feig; Wei Zhang; Lajos Pusztai; W Fraser Symmans; Yun Wu; Ralph B Arlinghaus
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

4.  Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells.

Authors:  G P Dotto; R A Weinberg; A Ariza
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

5.  The Angiogenic Secretome in VEGF overexpressing Breast Cancer Xenografts.

Authors:  Louis Dore-Savard; Esak Lee; Samata Kakkad; Aleksander S Popel; Zaver M Bhujwalla
Journal:  Sci Rep       Date:  2016-12-20       Impact factor: 4.379

6.  Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.

Authors:  Adviti Naik; Noura Al-Zeheimi; Charles Saki Bakheit; Marwa Al Riyami; Adil Al Jarrah; Mansour S Al Moundhri; Zamzam Al Habsi; Maysoon Basheer; Sirin A Adham
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

7.  Cancer-Associated Fibroblasts Correlate with Tumor-Associated Macrophages Infiltration and Lymphatic Metastasis in Triple Negative Breast Cancer Patients.

Authors:  Jing Zhou; Xiao-Hua Wang; Yi-Xin Zhao; Cheng Chen; Xin-Yun Xu; Qi Sun; Hong-Yan Wu; Ming Chen; Jian-Feng Sang; Lei Su; Xiao-Qiao Tang; Xian-Biao Shi; Yin Zhang; Qiao Yu; Yong-Zhong Yao; Wei-Jie Zhang
Journal:  J Cancer       Date:  2018-11-24       Impact factor: 4.207

8.  Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, fibroblasts and tumor vasculature.

Authors:  Kerri-Ann Norton; Kideok Jin; Aleksander S Popel
Journal:  J Theor Biol       Date:  2018-05-08       Impact factor: 2.691

Review 9.  Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.

Authors:  Jagdeep K Singh; Bruno M Simões; Sacha J Howell; Gillian Farnie; Robert B Clarke
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

10.  Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.

Authors:  Kideok Jin; Niranjan B Pandey; Aleksander S Popel
Journal:  Breast Cancer Res       Date:  2018-06-14       Impact factor: 6.466

View more
  5 in total

Review 1.  Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.

Authors:  Qiaorui Tan; Sha Yin; Dongdong Zhou; Yajing Chi; Xiaochu Man; Huihui Li
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

2.  NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network.

Authors:  Jie Chen; Yan Wang; Weimin Zhang; Di Zhao; Lingyuan Zhang; Jing Zhang; Jiawen Fan; Qimin Zhan
Journal:  Clin Transl Med       Date:  2021-08

Review 3.  NGAL as a Potential Target in Tumor Microenvironment.

Authors:  Elvira Crescenzi; Antonio Leonardi; Francesco Pacifico
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

Review 4.  Role of Serine Proteases at the Tumor-Stroma Interface.

Authors:  Ravichandra Tagirasa; Euna Yoo
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

5.  Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.

Authors:  Jaclyn M Einstein; Mark Perelis; Isaac A Chaim; Jitendra K Meena; Julia K Nussbacher; Alexandra T Tankka; Brian A Yee; Heyuan Li; Assael A Madrigal; Nicholas J Neill; Archana Shankar; Siddhartha Tyagi; Thomas F Westbrook; Gene W Yeo
Journal:  Mol Cell       Date:  2021-07-02       Impact factor: 19.328

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.